In the April–June 2016 edition of Corporate Disputes, Dr. Gregory K. Bell discusses disputes in the healthcare and life sciences industry. In this roundtable discussion, the panel experts describe the underlying causes of recent disputes in the sector and highlight key cases. To read the article, click the link below.
Beyond the single asset: The rise of combination and synergistic innovation in neurology drug development
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...